As Galapagos picks Gosebruch to lead spinout, Stoffels announces planned retirement

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said Monday afternoon that Paul Stoffels will retire as CEO within the next 12 months once the biotech identifies his successor. He will remain chairman of the company, which is sharpening its focus on cell therapies and spinning out other programs into a newly formed entity. Stoffels, a former CSO of Johnson & Johnson (NYSE:JNJ), joined Galapagos in 2022.

Also late Monday, Galapagos named former Neumora Inc. (NASDAQ:NMRA) President and CEO Henry Gosebruch CEO of the spinout, which will have nearly €2.5 billion ($2.5 billion) in cash to in-license programs in oncology, immunology and virology. Galapagos created the spinout as part of a reworked alliance with Gilead Sciences Inc. (NASDAQ:GILD), which will be a shareholder...